As reported by the Pharma Times, the Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has revealed support for AstraZeneca’s nasal spray flu treatment in the EU.
The flu vaccine, which was originally developed by AZ’s MedImmune unit, is already sold in the USA under the name FluMist.
Positive feedback from the CHMP came as a result of 73 global clinical studies and the US post-marketing studies which included objectives such as clinical safety and tolerability, clinical efficacy and effectiveness, and immunogenicity.
Are you looking for a new position in pharmaceuticals? Click here to search CK Science’s current pharmaceutical jobs online now.